[Novel Therapy in Guillain-Barré Syndrome].

The efficacy of plasma exchange (PE) and intravenous immunoglobulin (IVIg) therapies for Guillain-Barré syndrome have been established by numerous randomized controlled trials. However, 10-20 % of GBS patients cannot walk without aid after one year from onset of the disease. Thus, new treatment is required for these intractable cases. The Japan GBS outcome study (J-GOS) has been conducted to identify clinical or biological markers that predict the prognosis of Japanese GBS patients at an early stage. In the future, we expect to provide intractable patients so predicted with novel therapy, including molecular target drugs.